Polymyositis and dermatomyositis in Sarawak: a profile of patients treated in the Sarawak general hospital
Identifieur interne : 001522 ( Main/Exploration ); précédent : 001521; suivant : 001523Polymyositis and dermatomyositis in Sarawak: a profile of patients treated in the Sarawak general hospital
Auteurs : C. L. Teh [Malaisie] ; J. S. Wong [Malaisie] ; H. H. Soo [Malaisie]Source :
- Rheumatology International [ 0172-8172 ] ; 2012-01-01.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Antirhumatismaux (usage thérapeutique), Biopsie, Dermatomyosite (diagnostic), Dermatomyosite (traitement médicamenteux), Dermatomyosite (épidémiologie), Facteurs temps, Femelle, Humains, Hydroxychloroquine (usage thérapeutique), Hôpitaux généraux (), Malaisie, Muscles squelettiques (anatomopathologie), Mâle, Polymyosite (diagnostic), Polymyosite (traitement médicamenteux), Polymyosite (épidémiologie), Prednisolone (usage thérapeutique), Prévalence, Sujet âgé, Électromyographie, Études de suivi, Études rétrospectives, Études transversales.
- MESH :
- anatomopathologie : Muscles squelettiques.
- diagnostic : Dermatomyosite, Polymyosite.
- traitement médicamenteux : Dermatomyosite, Polymyosite.
- usage thérapeutique : Antirhumatismaux, Hydroxychloroquine, Prednisolone.
- épidémiologie : Dermatomyosite, Polymyosite.
- Adulte d'âge moyen, Biopsie, Facteurs temps, Femelle, Humains, Hôpitaux généraux, Malaisie, Mâle, Prévalence, Sujet âgé, Électromyographie, Études de suivi, Études rétrospectives, Études transversales.
- Wicri :
- geographic : Malaisie.
English descriptors
- KwdEn :
- Aged, Antirheumatic Agents (therapeutic use), Biopsy, Cross-Sectional Studies, Dermatomyositis, Dermatomyositis (diagnosis), Dermatomyositis (drug therapy), Dermatomyositis (epidemiology), Electromyography, Female, Follow-Up Studies, Hospitals, General (statistics & numerical data), Humans, Hydroxychloroquine (therapeutic use), Malaysia, Male, Malignancy, Middle Aged, Muscle, Skeletal (pathology), Polymyositis, Polymyositis (diagnosis), Polymyositis (drug therapy), Polymyositis (epidemiology), Prednisolone (therapeutic use), Prevalence, Retrospective Studies, Time Factors.
- MESH :
- chemical , therapeutic use : Antirheumatic Agents, Hydroxychloroquine, Prednisolone.
- geographic : Malaysia.
- diagnosis : Dermatomyositis, Polymyositis.
- drug therapy : Dermatomyositis, Polymyositis.
- epidemiology : Dermatomyositis, Polymyositis.
- pathology : Muscle, Skeletal.
- statistics & numerical data : Hospitals, General.
- Aged, Biopsy, Cross-Sectional Studies, Electromyography, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prevalence, Retrospective Studies, Time Factors.
Abstract
Abstract: We performed a cross-sectional study of the demography, clinical and laboratory features of patients with polymyositis and dermatomyositis followed up in our centre from 2006 to 2009. There were 12 cases, with the majority of them (58.3%) being woman. They have a mean age of 57.8 years and mean disease duration of 11.83 (SD 9.92) months. Our patients comprised of multi-ethnic groups with predominantly Chinese (83.3%), Sarawak natives (8.3%) and Malays (8.3%). They have a mean lag time to diagnosis of 3.67 (SD 4.27) months. Nine (75%) patients had dermatomyositis and 3(25%) had polymyositis. The common clinical manifestations found in our patients were proximal myopathy (100%), neck weakness (33.3%), dysphagia (33.3%) and interstitial lung disease (33.3%). For the nine patients with dermatomyositis, the most common dermatological manifestations were shawl sign (88.9%) and V sign (88.9%). Muscle enzymes were raised in 91.7% of patients. Electromyographies were carried out in four patients, and only one of our patients had muscle biopsy. Only 41.7% of our patients have positive ANA. The majority received prednisolone (100%) and hydroxychloroquine (58.3%). Malignancy occurred in five (three nasopharyngeal carcinomas, one sigmoid colon cancer and one lung cancer) out of the nine dermatomyositis patients but none in the polymyositis group. The mortality rate in our group was 4(33.3%) over the 4-year period. This study demonstrated the rarity of PM/DM in our centre with considerable lag time to diagnosis in our patients. Despite lack of muscle biopsy in our centre, our centre achieved appropriate diagnosis and management of PM/DM.
Url:
DOI: 10.1007/s00296-010-1745-2
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000813
- to stream Istex, to step Curation: 000813
- to stream Istex, to step Checkpoint: 000498
- to stream PubMed, to step Corpus: 000383
- to stream PubMed, to step Curation: 000383
- to stream PubMed, to step Checkpoint: 000350
- to stream Ncbi, to step Merge: 000151
- to stream Ncbi, to step Curation: 000151
- to stream Ncbi, to step Checkpoint: 000151
- to stream Main, to step Merge: 001524
- to stream Main, to step Curation: 001522
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Polymyositis and dermatomyositis in Sarawak: a profile of patients treated in the Sarawak general hospital</title><author><name sortKey="Teh, C L" sort="Teh, C L" uniqKey="Teh C" first="C. L." last="Teh">C. L. Teh</name></author><author><name sortKey="Wong, J S" sort="Wong, J S" uniqKey="Wong J" first="J. S." last="Wong">J. S. Wong</name></author><author><name sortKey="Soo, H H" sort="Soo, H H" uniqKey="Soo H" first="H. H." last="Soo">H. H. Soo</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6AAFE2B2AA57AC64EAB58D0070DC4BC6DC2CE739</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1007/s00296-010-1745-2</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-NHMDB8ZP-J/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000813</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000813</idno><idno type="wicri:Area/Istex/Curation">000813</idno><idno type="wicri:Area/Istex/Checkpoint">000498</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000498</idno><idno type="wicri:doubleKey">0172-8172:2011:Teh C:polymyositis:and:dermatomyositis</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:21243497</idno><idno type="wicri:Area/PubMed/Corpus">000383</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000383</idno><idno type="wicri:Area/PubMed/Curation">000383</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000383</idno><idno type="wicri:Area/PubMed/Checkpoint">000350</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000350</idno><idno type="wicri:Area/Ncbi/Merge">000151</idno><idno type="wicri:Area/Ncbi/Curation">000151</idno><idno type="wicri:Area/Ncbi/Checkpoint">000151</idno><idno type="wicri:Area/Main/Merge">001524</idno><idno type="wicri:Area/Main/Curation">001522</idno><idno type="wicri:Area/Main/Exploration">001522</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Polymyositis and dermatomyositis in Sarawak: a profile of patients treated in the Sarawak general hospital</title><author><name sortKey="Teh, C L" sort="Teh, C L" uniqKey="Teh C" first="C. L." last="Teh">C. L. Teh</name><affiliation wicri:level="1"><country xml:lang="fr">Malaisie</country><wicri:regionArea>Unit of Rheumatology, Department of Medicine, Sarawak General Hospital, Jalan Hospital, 93450, Kuching, Sarawak</wicri:regionArea><wicri:noRegion>Sarawak</wicri:noRegion></affiliation><affiliation></affiliation></author><author><name sortKey="Wong, J S" sort="Wong, J S" uniqKey="Wong J" first="J. S." last="Wong">J. S. Wong</name><affiliation wicri:level="1"><country xml:lang="fr">Malaisie</country><wicri:regionArea>Unit of Rheumatology, Department of Medicine, Sarawak General Hospital, Jalan Hospital, 93450, Kuching, Sarawak</wicri:regionArea><wicri:noRegion>Sarawak</wicri:noRegion></affiliation></author><author><name sortKey="Soo, H H" sort="Soo, H H" uniqKey="Soo H" first="H. H." last="Soo">H. H. Soo</name><affiliation wicri:level="1"><country xml:lang="fr">Malaisie</country><wicri:regionArea>Soo’s Neurology Clinic, Sarawak</wicri:regionArea><wicri:noRegion>Sarawak</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Rheumatology International</title><title level="j" type="sub">Clinical and Experimental Investigations</title><title level="j" type="abbrev">Rheumatol Int</title><idno type="ISSN">0172-8172</idno><idno type="eISSN">1437-160X</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="2012-01-01">2012-01-01</date><biblScope unit="volume">32</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="265">265</biblScope><biblScope unit="page" to="268">268</biblScope></imprint><idno type="ISSN">0172-8172</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0172-8172</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antirheumatic Agents (therapeutic use)</term><term>Biopsy</term><term>Cross-Sectional Studies</term><term>Dermatomyositis</term><term>Dermatomyositis (diagnosis)</term><term>Dermatomyositis (drug therapy)</term><term>Dermatomyositis (epidemiology)</term><term>Electromyography</term><term>Female</term><term>Follow-Up Studies</term><term>Hospitals, General (statistics & numerical data)</term><term>Humans</term><term>Hydroxychloroquine (therapeutic use)</term><term>Malaysia</term><term>Male</term><term>Malignancy</term><term>Middle Aged</term><term>Muscle, Skeletal (pathology)</term><term>Polymyositis</term><term>Polymyositis (diagnosis)</term><term>Polymyositis (drug therapy)</term><term>Polymyositis (epidemiology)</term><term>Prednisolone (therapeutic use)</term><term>Prevalence</term><term>Retrospective Studies</term><term>Time Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Biopsie</term><term>Dermatomyosite (diagnostic)</term><term>Dermatomyosite (traitement médicamenteux)</term><term>Dermatomyosite (épidémiologie)</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Hôpitaux généraux ()</term><term>Malaisie</term><term>Muscles squelettiques (anatomopathologie)</term><term>Mâle</term><term>Polymyosite (diagnostic)</term><term>Polymyosite (traitement médicamenteux)</term><term>Polymyosite (épidémiologie)</term><term>Prednisolone (usage thérapeutique)</term><term>Prévalence</term><term>Sujet âgé</term><term>Électromyographie</term><term>Études de suivi</term><term>Études rétrospectives</term><term>Études transversales</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antirheumatic Agents</term><term>Hydroxychloroquine</term><term>Prednisolone</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Malaysia</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Muscles squelettiques</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dermatomyositis</term><term>Polymyositis</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Dermatomyosite</term><term>Polymyosite</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dermatomyositis</term><term>Polymyositis</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Dermatomyositis</term><term>Polymyositis</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Muscle, Skeletal</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Hospitals, General</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Dermatomyosite</term><term>Polymyosite</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antirhumatismaux</term><term>Hydroxychloroquine</term><term>Prednisolone</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Dermatomyosite</term><term>Polymyosite</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Biopsy</term><term>Cross-Sectional Studies</term><term>Electromyography</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prevalence</term><term>Retrospective Studies</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Biopsie</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Hôpitaux généraux</term><term>Malaisie</term><term>Mâle</term><term>Prévalence</term><term>Sujet âgé</term><term>Électromyographie</term><term>Études de suivi</term><term>Études rétrospectives</term><term>Études transversales</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Malaisie</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: We performed a cross-sectional study of the demography, clinical and laboratory features of patients with polymyositis and dermatomyositis followed up in our centre from 2006 to 2009. There were 12 cases, with the majority of them (58.3%) being woman. They have a mean age of 57.8 years and mean disease duration of 11.83 (SD 9.92) months. Our patients comprised of multi-ethnic groups with predominantly Chinese (83.3%), Sarawak natives (8.3%) and Malays (8.3%). They have a mean lag time to diagnosis of 3.67 (SD 4.27) months. Nine (75%) patients had dermatomyositis and 3(25%) had polymyositis. The common clinical manifestations found in our patients were proximal myopathy (100%), neck weakness (33.3%), dysphagia (33.3%) and interstitial lung disease (33.3%). For the nine patients with dermatomyositis, the most common dermatological manifestations were shawl sign (88.9%) and V sign (88.9%). Muscle enzymes were raised in 91.7% of patients. Electromyographies were carried out in four patients, and only one of our patients had muscle biopsy. Only 41.7% of our patients have positive ANA. The majority received prednisolone (100%) and hydroxychloroquine (58.3%). Malignancy occurred in five (three nasopharyngeal carcinomas, one sigmoid colon cancer and one lung cancer) out of the nine dermatomyositis patients but none in the polymyositis group. The mortality rate in our group was 4(33.3%) over the 4-year period. This study demonstrated the rarity of PM/DM in our centre with considerable lag time to diagnosis in our patients. Despite lack of muscle biopsy in our centre, our centre achieved appropriate diagnosis and management of PM/DM.</div></front></TEI><affiliations><list><country><li>Malaisie</li></country></list><tree><country name="Malaisie"><noRegion><name sortKey="Teh, C L" sort="Teh, C L" uniqKey="Teh C" first="C. L." last="Teh">C. L. Teh</name></noRegion><name sortKey="Soo, H H" sort="Soo, H H" uniqKey="Soo H" first="H. H." last="Soo">H. H. Soo</name><name sortKey="Wong, J S" sort="Wong, J S" uniqKey="Wong J" first="J. S." last="Wong">J. S. Wong</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001522 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001522 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:6AAFE2B2AA57AC64EAB58D0070DC4BC6DC2CE739
|texte= Polymyositis and dermatomyositis in Sarawak: a profile of patients treated in the Sarawak general hospital
}}
| This area was generated with Dilib version V0.6.33. |  |